---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-088065"
form_type: "8-K"
ticker: null
cik: "0001708331"
company_name: "Virpax Pharmaceuticals, Inc."
filed_at: "2023-11-17T23:59:59+00:00"
generated_at: "2026-06-08T00:11:46.002728+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Virpax CEO Anthony Mack resigns due to ongoing litigation; Gerald Bruce named CEO, Eric Floyd Chairman

## Summary
- Anthony P. Mack resigned as CEO and Chairman effective November 17, 2023; resignation due to ongoing litigation.
- Board appointed Gerald Bruce as CEO and Dr. Eric Floyd as Chairman, effective November 20, 2023.
- Gerald Bruce had served as EVP of Commercial Operations since 2017 and as President/CEO of subsidiary Novvae Pharmaceuticals.
- Dr. Eric Floyd, a board member since 2017, has over 25 years of pharmaceutical regulatory experience.
- Compensation for new CEO and Chairman has not yet been determined.

## SEC filing metadata
- accession: 0001213900-23-088065
- form_type: 8-K
- cik: 0001708331
- company_name: Virpax Pharmaceuticals, Inc.
- filed_at: 2023-11-17T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708331/000121390023088065/0001213900-23-088065-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708331/000121390023088065/ea188635-8k_virpaxpharma.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-088065
- JSON: https://secwatch.observer/filing/0001213900-23-088065.json
- Plain text: https://secwatch.observer/filing/0001213900-23-088065.txt

## Key facts
- Executive change
  Gerald Bruce was appointed as Chief Executive Officer at Virpax Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: On November 15, 2023, the Company’s Board appointed Gerald Bruce as CEO and Dr. Eric Floyd as Chair of the Board, effective as of November 20, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708331/000121390023088065/0001213900-23-088065-index.htm
- Executive change
  Dr. Eric Floyd was appointed as Chair of the Board at Virpax Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Chair of the Board
  source text: On November 15, 2023, the Company’s Board appointed Gerald Bruce as CEO and Dr. Eric Floyd as Chair of the Board, effective as of November 20, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708331/000121390023088065/0001213900-23-088065-index.htm
- Executive change
  Anthony P. Mack resigned as Chief Executive Officer and Chair of the Board at Virpax Pharmaceuticals, Inc..
  - Action: resigned
  - Role: Chief Executive Officer and Chair of the Board
  source text: On November 15, 2023, Virpax Pharmaceuticals, Inc. (the “Company”) accepted the resignation of Anthony P. Mack as Chief Executive Officer (“CEO”) and Chair of the Board of Directors (the “Board”) of the Company effective November 17, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708331/000121390023088065/0001213900-23-088065-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.